Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Axcella Health Inc (AXLA)

Axcella Health Inc (AXLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,554
  • Shares Outstanding, K 52,576
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,630 K
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.97
Trade AXLA with:

Options Overview Details

View History
  • Implied Volatility 121.38% ( -3.14%)
  • Historical Volatility 71.41%
  • IV Percentile 54%
  • IV Rank 10.54%
  • IV High 866.28% on 05/16/22
  • IV Low 33.59% on 02/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 70
  • Volume Avg (30-Day) 72
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 3,010
  • Open Int (30-Day) 2,038

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate -0.35
  • Low Estimate -0.38
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +29.28%
on 07/29/22
2.64 -11.31%
on 08/04/22
+0.19 (+8.84%)
since 07/11/22
3-Month
1.35 +73.33%
on 05/13/22
2.79 -16.13%
on 06/09/22
+0.85 (+57.05%)
since 05/11/22
52-Week
1.35 +73.33%
on 05/13/22
4.40 -46.82%
on 10/26/21
-1.05 (-30.97%)
since 08/11/21

Most Recent Stories

More News
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 2.34 (-0.43%)
PLRX : 20.53 (-6.47%)
FRLN : 0.9598 (-1.49%)
ABSI : 4.79 (+14.05%)
DICE : 20.57 (+0.88%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 2.34 (-0.43%)
PLRX : 20.53 (-6.47%)
FRLN : 0.9598 (-1.49%)
ABSI : 4.79 (+14.05%)
DICE : 20.57 (+0.88%)
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 2.34 (-0.43%)
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program

Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies....

ALKS : 25.47 (-0.70%)
PRPH : 11.50 (+7.58%)
SESN : 0.7040 (+0.11%)
AXLA : 2.34 (-0.43%)
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 2.34 (-0.43%)
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 2.34 (-0.43%)
Axcella Reports First Quarter Financial Results and Provides Business Update

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 2.34 (-0.43%)
Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

BIIB : 218.22 (-1.28%)
ZSAN : 0.5576 (+7.23%)
AXLA : 2.34 (-0.43%)
APLT : 1.3300 (+7.26%)
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly....

JAZZ : 154.25 (-2.02%)
AXSM : 45.32 (-6.29%)
TRVI : 4.27 (+0.23%)
AXLA : 2.34 (-0.43%)
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

TGTX : 7.52 (-5.53%)
VYGR : 6.48 (-2.56%)
TRVI : 4.27 (+0.23%)
AXLA : 2.34 (-0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company's principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical...

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.42
1st Resistance Point 2.38
Last Price 2.34
1st Support Level 2.30
2nd Support Level 2.26
3rd Support Level 2.22

See More

52-Week High 4.40
Fibonacci 61.8% 3.23
Fibonacci 50% 2.87
Fibonacci 38.2% 2.52
Last Price 2.34
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar